Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
CC transcript
|
|
Larimar Therapeutics, Inc. (ZFGN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/12/2022 |
8-K
| Quarterly results |
| 06/02/2020 |
8-K
| Appointed a new director|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 28, 2020 Larimar Therapeutics, Inc. Delaware 001-36510 20-3857670 Three Bala Plaza East. Suite 506 Bala Cynwyd, Pennsylvania 19004 Registrant's telephone number, including area code: 511-9056 Zafgen, Inc. Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act...",
"Certificate of Amendment of Ninth Amended and Restated Certificate of Incorporation Of Zafgen, Inc. related to the Reverse Stock Split, (filed herewith)",
"Certificate of Amendment of Ninth Amended and Restated Certificate of Incorporation Of Zafgen, Inc. related to the Name Change, (filed herewith)",
"Form of Pre-Funded Warrant (filed herewith)",
"Securities Purchase Agreement, by and among Larimar Therapeutics, Inc. and the investors listed on the Schedule of Investors attached thereto (filed herewith)",
"Registration Rights Agreement, by and among Larimar Therapeutics, Inc. and certain Investors (filed herewith)",
"Form of Indemnification Agreement between the Company and its directors (filed herewith)",
"Employment Agreement, by and between the Company and Michael Celano (filed herewith)",
"Code of Conduct (filed herewith)",
"Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics" |
|
| 03/08/2016 |
8-K
| Form 8-K - Current report |
| 09/30/2015 |
8-K
| Appointed a new director |
| 09/18/2014 |
8-K
| Appointed a new director |
| 06/24/2014 |
8-K
| Appointed a new director |
|
|